GORE TAG可贴合胸主动脉支架十年单中心经验
该回顾性单中心研究分析了2009年至2018年间194例使用GORE TAG可贴合胸主动脉支架行TEVAR的患者,中位随访43.5个月。结果显示远期生存率良好,主动脉破裂和再干预累积发生率可控,无新发支架感染或材料疲劳。
要点
- CTAG支架在多种胸主动脉疾病中显示良好的远期安全性和有效性。
- 中位随访43.5个月,60个月生存率56.6%,主动脉破裂累积发生率11.9%。
- 主动脉相关再干预累积发生率27.5%,支架移位累积发生率低(60个月2.8%)。
核心结论
- CTAG支架在长期随访中表现出持续的安全性、有效性和临床耐久性。
研究设计与样本
- 回顾性单中心研究,纳入2009年1月至2018年12月间194例使用CTAG行TEVAR的患者,男性57.2%,平均年龄65±13岁。
主要发现
- 总体生存率12个月为75.8%(95%CI 0.76-0.70),60个月为56.6%(95%CI 0.57-0.50)。
- 主动脉破裂累积发生率在60和90个月均为11.9%(95%CI 0.07-0.17)。
- 主动脉相关再干预累积发生率在60和90个月均为27.5%(95%CI 0.21-0.34)。
- 支架移位累积发生率60个月为2.8%(95%CI 0.004-0.05),90个月为3.9%(95%CI 0.007-0.07)。
- 未观察到新发支架感染或材料疲劳。
临床怎么用
- 对于适合TEVAR的胸主动脉疾病患者,CTAG支架可作为安全有效的治疗选择,但需注意远期再干预风险。
局限性
- 回顾性单中心设计可能限制结果的普遍性。
- 中位随访时间43.5个月,部分患者随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to report 10-year real-world single-center experience with the GORE TAG conformable thoracic aortic graft (CTAG), focusing on rupture-free survival, aortic-related reintervention, and device-related complications during midterm and long-term follow-up (FU). METHODS: This retrospective study analyzes results of thoracic endovascular aortic repair (TEVAR) performed between January 2009 and December 2018. Out of 419 TEVAR procedures within this period, 194 patients (male 57.2%, 111/194), with a mean age of 65 ± 13 years, were treated with the CTAG device. Indication for TEVAR was a thoracic aortic aneurysm in 24.7% (48/194), type B aortic dissection in 32.5% (63/194), penetrating aortic ulcer 15.5% (30/194), and miscellaneous 27.3% (53/194). Emergently were operated 43.8% (85/194) patients. Median follow-up (FU) including computed tomography imaging was 43.5 months (Q1-Q3: 8.6-67.0) and was completed in 91.2% (177/194) of patients. RESULTS: Overall survival rates were 75.8% (95% confidence interval [CI] = [0.76-0.70]) and 56.6% (95% CI = [0.57-0.50]) at 12 and 60 months, respectively. Cumulative incidence for aortic rupture was 11.9% (95% CI = [0.07-0.17]) at 60 and 90 months, respectively. Cumulative incidence for aortic-related reintervention was 27.5% (95% CI = [0.21-0.34]) at 60 and 90 months. Cumulative incidence for migration was 2.8% (95% CI = [0.004-0.05]) and 3.9% (95% CI = [0.007-0.07]) at 60 and 90 months, respectively. New endograft infections or material fatigue were not observed. CONCLUSIONS: The herein reported 10-year real-world single-center experience with the CTAG observed favorable long-term outcome. Thus, the device demonstrates appropriate persistent safety, efficacy, and clinical durability up to long-term FU in the treatment of diverse thoracic aortic pathologies.
引用
- Skrypnik D, Bischoff MS, Meisenbacher K, et al. A 10-Year Single-Center Experience With the GORE TAG Conformable Thoracic Stent Graft in the Treatment of Thoracic Aortic Disease. J Endovasc Ther. 2021. PMID: 34632839. doi:10.1177/15266028211049340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。